Search

Your search keyword '"Aldinio, Victoria"' showing total 26 results
Start Over Author "Aldinio, Victoria"
26 results on '"Aldinio, Victoria"'

4. Treatment of Alzheimer’s Disease in the New Era of Monoclonal Antibodies Against Cerebral Amyloid-β: Pharmacological Prescription and Knowledge in Argentina

Author

Cubas Guillen, Jonathan, Rojas, Galeno, Demey, Ignacio, Sarasola, Diego, Merchán del Hierro, Xavier, Persi, Gabriel, Aldinio, Victoria, Pereira de Silva, Nahuel, Fernández Boccazzi, Julián, Seguí, Josefina, Muniagurria, Santiago, Gilbert, Afra, and Gatto, Emilia

Abstract

Background: Alzheimer’s disease (AD) presents a significant global health challenge. Understanding the current and upcoming treatment landscape is crucial for effectively managing patients.Objective: The aim of this study was to assess the pattern of prescription and knowledge about new therapies by physicians who treat AD patients in Argentina.Methods: A cross- sectional and analytic study was conducted. A survey was elaborated about pharmacological treatment in AD. Statistical analysis of answers of specialists in cognitive disorders (SCD), non-specialists in cognitive disorders (NSCD), recommended treatment, non-recommended treatment (NRT), and off-labeltreatment was performed.Results: 155 physicians answered the survey. A 19.35%prescribed at least one NRT for dementia. 78.06%prescribed at least an off-labeltreatment or an NRT for mild cognitive impairment (MCI). 31%would prescribe monoclonal antibodies (MABs) against cerebral amyloid-β (Aβ) to AD patients, and 42.6%responded that they were not aware of any adverse effect of these. Quetiapine was the most frequent treatment for psychotic symptoms (88.4%) and escitalopram (32.3%) for apathy. A 70%of potential prescribers of MABs (n= 100) would request biomarkers of cerebral Aβ in the initial assessment. There were significant differences between the responses of SCD and NSCD regarding the prescription of MABs (52.17%versus 23.08, respectively) and knowledge about adverse events (76.09%versus 38.46%, respectively).Conclusions: A considerable percentage of physicians indicated NRT and off-labelmedication in MCI and dementia. In Argentina, there are many physicians who would indicate a MABs for AD, but many are not completely aware of its safety profile.

Published
2024
Full Text
View/download PDF

5. Vitamin B12 deficiency and cognitive impairment: Is there a distinctive cognitive domain affected? A descriptive study in Buenos Aires

Author

Boccazzi, Julian Fernandez, primary, Rojas, Galeno, additional, Guillen, Jonathan Cubas, additional, Gatto, Emilia, additional, Persi, Gabriel Gustavo, additional, Hierro, Xavier Merchan, additional, Aldinio, Victoria, additional, Seguí, Josefina, additional, Camino, Victoria, additional, Muniagurria, Santiago, additional, Gilbert, Afra, additional, de Silva, Nahuel Pereira, additional, and Eizaguirre, Barbara, additional

Published
2023
Full Text
View/download PDF

6. Pharmacological treatment and use of monoclonal antibodies in Alzheimer’s disease: Analysis on a medical management in Argentina

Author

Guillen, Jonathan Cubas, primary, Rojas, Galeno, additional, Demey, Ignacio, additional, Sarasola, Diego, additional, del Hierro, Xavier Merchan, additional, Persi, Gabriel Gustavo, additional, Aldinio, Victoria, additional, de Silva, Nahuel Pereira, additional, Boccazzi, Julian Fernandez, additional, Seguí, Josefina, additional, Muniagurria, Santiago, additional, Gilbert, Afra, additional, and Gatto, Emilia, additional

Published
2023
Full Text
View/download PDF

10. Identificación del síndrome de piernas inquietas en estudios polisomnográficos y su asociación con otras variables

Author

Aldinio, Victoria, primary, Merchán del Hierro, Xavier, additional, Muniagurria, Santiago, additional, Persi, Gabriel Gustavo, additional, Pereira de Silva, Nahuel Fernando, additional, Camino, María Victoria, additional, Cubas Guillen, Jonathan Fernando, additional, Fernández Boccazzi, Julian, additional, Seguí, Josefina, additional, and Gatto de Membrives, Emilia Mabel, additional

Published
2022
Full Text
View/download PDF

11. Pharmacovigilance in Neuroscience

Author

Sánchez-de-Paz, María-Pilar, primary, Da-Prat-de-Magalhaes, Gustavo, additional, Isa, Santiago, additional, Aldinio, Victoria, additional, Norberto-Latella, Andres, additional, Mabel-Gatto, Emilia, additional, and Rojas, Galeno J., additional

Published
2021
Full Text
View/download PDF

12. Cognitive impairment in physicians suffering burnout syndrome: A matter of moral Injury

Author

Martino, Gabriel Gerardo, primary, Rojas, Galeno, additional, Zuin, Daniel, additional, Persi, Gabriel Gustavo, additional, Leis, Adriana, additional, Macri, Ana Macarena, additional, Camino, María Victoria, additional, Parisi, Virginia Laura, additional, Silva, Nahuel Pereira, additional, Gatto, Emilia, additional, Aldinio, Victoria, additional, Guillen, Jonathan Cubas, additional, and Boccazzi, Julián Fernández, additional

Published
2020
Full Text
View/download PDF

17. Sertraline-induced Hemichorea

Author

Gatto, Emilia Mabel, Aldinio, Victoria, Parisi, Virginia, Persi, Gabriel, Da Prat, Gustavo, Bres Bullrich, Maria, Sanchez, Pilar, and Rojas, Galeno

Subjects
Hemichorea-hemiballism, Depressive Disorder, Dyskinesia, Drug-Induced, lcsh:Diseases of the musculoskeletal system, Dyskinesias, Case study, Hemichorea, Case Reports, lcsh:RC346-429, Diagnosis, Differential, Neurology, selective serotonin reuptake inhibitors, Chorea, Sertraline, Tremor, Humans, Female, Sertraline-induced hemichorea, lcsh:RC925-935, lcsh:Neurology. Diseases of the nervous system, Serotonin uptake inhibitors, Aged
Abstract

Background: Hemichorea–hemiballism is a syndrome secondary to different etiologies. Drug-induced hemichorea is a rare syndrome related to selective serotonin reuptake inhibitors. To the best of our knowledge, no previous cases of hemichorea associated with sertraline have been reported. Case Report: A 65-year-old female noticed hemichorea 1 week after initiation of sertraline. After extensive investigations, other causes of hemichorea were excluded. Hemichorea remitted after sertraline withdrawal. Discussion: In our patient, temporal association and the negative clinical assessment supported a diagnosis of likely drug-induced involuntary movement. We hypothesized that enhanced serotonergic transmission in the ventral tegmental area or nigrostriatum may be involved in sertraline-induced hemichorea., Tremor and Other Hyperkinetic Movements, Tremor and Other Hyperkinetic Movements

Published
2017
Full Text
View/download PDF

20. Sertraline-induced Hemichorea

Author

Gatto, Emilia M., primary, Aldinio, Victoria, additional, Parisi, Virginia, additional, Persi, Gabriel, additional, Da Prat, Gustavo, additional, Bullrich, Maria Bres, additional, Sanchez, Pilar, additional, and Rojas, Galeno, additional

Published
2017
Full Text
View/download PDF

23. Task specific dystonia in a juggler

Author

Ramírez Gómez, Carolina Candelaria, primary, Conti, Eugenia, additional, Montilla Uzcategui, Verónica, additional, Aldinio, Victoria, additional, and Micheli, Federico, additional

Published
2016
Full Text
View/download PDF

25. Distrofia muscular de Emery-Dreifuss: la importancia de un estudio ordenado a partir de la clínica y una correcta caracterización etiológico-molecular

Author

Zubiri, Victoria, primary, Gerardi, Omar, additional, Medina, Nancy, additional, Taratuto, Ana Lia, additional, Huamanchumo Fiestas, Janina, additional, Lopez, Matias, additional, Aldinio, Victoria, additional, Gargiulo, Guadalupe, additional, González Morón, Dolores, additional, Córdoba, Marta, additional, Rodríguez Quiroga, Sergio A., additional, Volman, Gabriel, additional, Kauffman, Marcelo A., additional, and Uccelli, Aquiles, additional

Published
2015
Full Text
View/download PDF

26. Moaning Phenomenon and Rapidly Progressive Dementia in Anti LGI-1 Associated Progressive Supranuclear Palsy Syndrome.

Author

Hierro XM, Rojas G, Aldinio V, Bres-Bullrich M, Da-Prat G, Ebner R, and Gatto EM

Subjects
Dementia drug therapy, Dementia immunology, Disease Progression, Glucocorticoids therapeutic use, Humans, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors therapeutic use, Male, Methylprednisolone therapeutic use, Middle Aged, Rituximab therapeutic use, Supranuclear Palsy, Progressive drug therapy, Supranuclear Palsy, Progressive immunology, Autoantibodies immunology, Dementia physiopathology, Supranuclear Palsy, Progressive physiopathology
Abstract

Background: Immunological causes of atypical parkinsonisms linked to neuronal specific antibodies have been recently reported. As these are potentially treatable disorders, it is desirable to identify which clinical features may suggest an autoimmune etiology., Case Report: A 60-year-old-man with progressive supranuclear palsy associated with anti-LGI-1 antibodies presented with rapidly progressive dementia and moaning. Treatment with steroids and immunoglobulin resulted in temporary clinical improvement and disease stabilization., Discussion: Anti-LGI-1 antibodies interfere with normal synaptic activity and maturation in the central nervous system. We suggest that an immune-mediated mechanism might be considered in atypical parkinsonisms with unusual features such as rapidly progressive dementia., Highlights: We present a case of rapidly evolving progressive supranuclear palsy-like parkinsonism associated with anti-LGI-1 antibodies, suggesting that immune-mediated mechanisms might be involved in rapid progression of some atypical parkinsonisms. This case also contributes to the expanding spectrum of moaning-associated disorders., Competing Interests: The authors have no competing interests to declare., (Copyright: © 2020 The Author(s).)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results